Evidence map›Paper›PMID 34689821›Full record

ArticleJournal of hematology & oncology2021

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.

Lorenzo Canti, Stéphanie Humblet-Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus, Leo Heyndrickx, Aurélie Henry, Sophie Servais, Evelyne Willems, Grégory Ehx and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Lorenzo Canti *Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
Stéphanie Humblet-Baron *Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
Isabelle Desombere *SD Infectious Diseases in Humans, Sciensano, 642 Engelandstraat, 1180, Ukkel, Belgium.
Julika Neumann *Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
Pieter PannusSD Infectious Diseases in Humans, Sciensano, 642 Engelandstraat, 1180, Ukkel, Belgium.
Leo HeyndrickxVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
Aurélie HenryDivision of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium.
Sophie ServaisLaboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
Evelyne WillemsDivision of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium.
Grégory EhxLaboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
Stanislas GorielyInstitute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.
Laurence SeidelDepartment of Biostatistics, University Hospital of Liège, Liège, Belgium.
Johan MichielsVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
Betty WillemsVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
Adrian ListonDepartment of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
Kevin K Ariën *Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
Yves Beguin *Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
Maria E Goossens *SD Infectious Diseases in Humans, Sciensano, 642 Engelandstraat, 1180, Ukkel, Belgium.
Arnaud Marchant *Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.
Frédéric Baron *Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium. f.baron@uliege.be.ORCID 0000-0002-2944-3812
University of Liège · BEInstituut voor Tropische Geneeskunde · BESciensano (Belgium) · BEKU Leuven · BEUniversité Libre de Bruxelles · BEBabraham Institute · GB

Funding

Université de Liège Crédits Sectoriels de Recherche en Sciences de la Santé (FSR 2021)
6 · The paper itself

Abstract

backgroundFactors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain to be elucidated.

methodsForty allo-HCT recipients were included in a study of immunization with BNT162b2 mRNA vaccine at days 0 and 21. Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD) were assessed at days 0, 21, 28, and 49 while neutralizing Ab against SARS-CoV-2 wild type (NT50) were assessed at days 0 and 49. Results observed in allo-HCT patients were compared to those obtained in 40 healthy adults naive of SARS-CoV-2 infection. Flow cytometry analysis of peripheral blood cells was performed before vaccination to identify potential predictors of Ab responses.

resultsThree patients had detectable anti-RBD Ab before vaccination. Among the 37 SARS-CoV-2 naive patients, 20 (54%) and 32 (86%) patients had detectable anti-RBD Ab 21 days and 49 days postvaccination. Comparing anti-RBD Ab levels in allo-HCT recipients and healthy adults, we observed significantly lower anti-RBD Ab levels in allo-HCT recipients at days 21, 28 and 49. Further, 49% of allo-HCT patients versus 88% of healthy adults had detectable NT50 Ab at day 49 while allo-HCT recipients had significantly lower NT50 Ab titers than healthy adults (P = 0.0004). Ongoing moderate/severe chronic GVHD (P < 0.01) as well as rituximab administration in the year prior to vaccination (P < 0.05) correlated with low anti-RBD and NT50 Ab titers at 49 days after the first vaccination in multivariate analyses. Compared to healthy adults, allo-HCT patients without chronic GVHD or rituximab therapy had comparable anti-RBD Ab levels and NT50 Ab titers at day 49. Flow cytometry analyses before vaccination indicated that Ab responses in allo-HCT patients were strongly correlated with the number of memory B cells and of naive CD4

conclusionsChronic GVHD and rituximab administration in allo-HCT recipients are associated with reduced Ab responses to BNT162b2 vaccination. Immunological markers could help identify allo-HCT patients at risk of poor Ab response to mRNA vaccination.

trial registrationThe study was registered at clinicaltrialsregister.eu on 11 March 2021 (EudractCT # 2021-000673-83).

Indexed as

AdultAgedAntibodies, NeutralizingBNT162 VaccineCOVID-19 VaccinesHematopoietic Stem Cell TransplantationHumansMiddle AgedTransplantation ConditioningTransplantation, HomologousTransplantation ImmunologyAntibodies, NeutralizingBNT162 VaccineCOVID-19 VaccinesAllogeneicBNT162b2 mRNA vaccineCOVID-19Hematopoietic cell transplantationPlasmacytoid dendritic cellsSARS-CoV-2Switched B cellsT-SNEVaccine

Identifiers

PMID34689821
PMCPMC8542409
OpenAlexW3208594704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.